Panagora Asset Management’s Kiora Pharmaceuticals KPRX Stock Holding History

Panagora Asset Management’s Portfolio KPRX Stock Details KPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-18	Closed	-$23K	–	2545
2019 Q2	$23K	Hold	18	–	–	﹤0.01%	2251
2019 Q1	$30K	Sell	18 -6	-25%	-$14.6K	﹤0.01%	2169
2018 Q4	$60K	Buy	24 +4	+20%	+$9.23K	﹤0.01%	1924
2018 Q3	$33K	Buy	+20	New	+$53.7K	﹤0.01%	2116

Other funds holding KPRX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

GSWM

Golden State Wealth Management Santa Ana, California $1.1B AUM 27.49% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Panagora Asset Management's KPRX Position: Q3 2019 in Review

Panagora Asset Management sold out of Kiora Pharmaceuticals (KPRX) in Q3 2019, closing a stake of 18 shares — an estimated $23K sold.

Panagora Asset Management first reported a position in KPRX in Q3 2018 and held it in 4 quarters. The position peaked at $60K in Q4 2018. 9 funds tracked by Wall St. Rank hold KPRX as of Q3 2019.

Panagora Asset Management reported no remaining Kiora Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Panagora Asset Management sold 18 Kiora Pharmaceuticals shares in Q3 2019, an estimated $23K.
Panagora Asset Management first reported a position in Kiora Pharmaceuticals in Q3 2018 and held it in 4 quarters.
Panagora Asset Management's Kiora Pharmaceuticals position peaked at $60K in Q4 2018.
9 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q3 2019.

Based on Panagora Asset Management's 13F filing for Q3 2019, filed 12 Nov 2019.